Supha Pharmachem (BOM:539561) Beneish M-Score: 4.28 (As of Jul. 02, 2026) — 282% Above Median


BOM:539561 Supha Pharmachem Ltd BOM:539561
58 GF Score
Price ₹0.30
GF Value ₹1.53
Valuation Possible Value Trap
! 12 Warning Signs
View Full Analysis

What is Supha Pharmachem Beneish M-Score?

Supha Pharmachem BOM:539561 -3.23% 58 Beneish M-Score is 4.28 as of Jul. 02, 2026, which is 282% above its 10-year median of 1.12. GuruFocus rates BOM:539561 with a GF Score™ of 58/100 and a GF Value™ of ₹1.53 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 909 Drug Manufacturers companies, Supha Pharmachem ranks worse than 97.8% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 4.28 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Supha Pharmachem's Beneish M-Score or its related term are showing as below:

BOM:539561' s Beneish M-Score Range Over the Past 10 Years
Min: -6.3   Med: 1.12   Max: 159.25
Current: 4.28

During the past 11 years, the highest Beneish M-Score of Supha Pharmachem was 159.25. The lowest was -6.30. And the median was 1.12.


Supha Pharmachem Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Supha Pharmachem's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supha Pharmachem Beneish M-Score Chart

Supha Pharmachem Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.52 1.12 -2.07 5.52 4.28

Supha Pharmachem Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 4.28 0.00 0.00

BOM:539561 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supha Pharmachem Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Supha Pharmachem's Beneish M-Score falls into.


BOM:539561
58GF Score
Supha Pharmachem Ltd BOM:539561
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supha Pharmachem Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Supha Pharmachem for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 8.3593+0.528 * 0.5683+0.404 * 1.5+0.892 * 0.1003+0.115 * 0.6706
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 14.1447+4.679 * 0.666445-0.327 * 0.9965
=4.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was ₹7,716 Mil.
Revenue was ₹4,053 Mil.
Gross Profit was ₹71 Mil.
Total Current Assets was ₹17,203 Mil.
Total Assets was ₹17,203 Mil.
Property, Plant and Equipment(Net PPE) was ₹0 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹0 Mil.
Selling, General, & Admin. Expense(SGA) was ₹17 Mil.
Total Current Liabilities was ₹16,765 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Net Income was ₹21 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹-11,444 Mil.
Total Receivables was ₹9,206 Mil.
Revenue was ₹40,417 Mil.
Gross Profit was ₹403 Mil.
Total Current Assets was ₹19,478 Mil.
Total Assets was ₹19,479 Mil.
Property, Plant and Equipment(Net PPE) was ₹0 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1 Mil.
Selling, General, & Admin. Expense(SGA) was ₹12 Mil.
Total Current Liabilities was ₹19,050 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7716.198 / 4052.511) / (9206.018 / 40417.067)
=1.904054 / 0.227776
=8.3593

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(403.314 / 40417.067) / (71.16 / 4052.511)
=0.009979 / 0.017559
=0.5683

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (17203.049 + 0.084) / 17203.49) / (1 - (19478.499 + 0.462) / 19479.236)
=2.1E-5 / 1.4E-5
=1.5

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4052.511 / 40417.067
=0.1003

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.567 / (0.567 + 0.462)) / (0.387 / (0.387 + 0.084))
=0.55102 / 0.821656
=0.6706

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.426 / 4052.511) / (12.3 / 40417.067)
=0.0043 / 0.000304
=14.1447

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 16764.58) / 17203.49) / ((0 + 19049.658) / 19479.236)
=0.974487 / 0.977947
=0.9965

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(21.294 - 0 - -11443.889) / 17203.49
=0.666445

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Supha Pharmachem has a M-score of 4.28 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 4.28 mean?
Supha Pharmachem (BOM:539561) has a Beneish M-Score of 4.28 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Supha Pharmachem and its competitors. This is 282% above median its historical median of 1.12. According to the industry distribution chart, Supha Pharmachem ranks #889 out of 909 companies in the Drug Manufacturers industry, placing it in the top 97.8%.
Is Supha Pharmachem's Beneish M-Score too high?
Supha Pharmachem's current Beneish M-Score of 4.28 is 282% above median its 10-year median of 1.12. Based on the distribution chart, Supha Pharmachem ranks #889 out of 909 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Supha Pharmachem has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #889 out of 909 companies for Beneish M-Score. This places Supha Pharmachem in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Supha Pharmachem and its competitors. Supha Pharmachem's current Beneish M-Score is 4.28, which is 282% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.53, compared to a current price of ₹0.30 — trading 80.4% below its estimated fair value. The current Beneish M-Score is 4.28, which is 282% above median its 10-year median of 1.12. Supha Pharmachem's overall GF Score™ is 58/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Beneish M-Score is 4.28 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supha Pharmachem (BOM:539561) Overvalued in 2026?

Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued. The current stock price of ₹0.30 is trading 80.4% below its estimated GF Value™ of ₹1.53. GuruFocus considers Supha Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:539561:

  • Beneish M-Score: 4.28 (282% above median its 10-year median of 1.12)
  • GF Value™: ₹1.53 vs. price of ₹0.30 (80.4% below fair value)
  • GF Score™: 58/100 with 12 warning signs

No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supha Pharmachem Business Description

Address Saugbaug Road, Office No. 9, Behind Ravi Vihar Hotel, K Raheja Prime, Marol Industrial Estate, Andheri (East), Mumbai, MH, IND, 400059
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
58GF Score

Get the complete analysis for BOM:539561

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.30
Price
₹1.53
GF Value